Iovance Biotherapeutics

American biopharmaceutical startup

IOVA Nasdaq ISIN US4622601007 SEC CIK 1425205
Follow Iovance Biotherapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $121.5M +80.1% vs same quarter last year
Net income −$22.3M +75.6% vs same quarter last year
EPS, diluted −$0.05 +80% vs same quarter last year
Operating cash flow −$4.5M +94.3% vs same quarter last year
Revenue by quarter
$73.7M
$49.3M
$60M
$67.5M
$86.8M
$71.4M
$99.3M
$121.5M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$600M−$400M−$200M$0$200M$400MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$263.5M−$391M
FY24$164.1M−$372.2M
FY23$1.2M−$444M
FY22-−$395.9M
FY21-−$342.3M
FY20-−$259.6M
FY19-−$197.6M
FY18$0−$123.6M
FY17$0−$92.1M
FY16$0−$52.9M
FY15$0−$27.7M
FY14$0−$12M
FY13$0−$25.4M
FY12$0−$3.3M
FY11$0−$25.7M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−40000%−30000%−20000%−10000%0%10000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2534.3%−153.1%−148.4%
FY2443.2%−240.9%−226.9%
FY2313.1%−38735%−37342.3%
FY22---
FY21---
FY20---
FY19---
FY18---
FY17---
FY16---
FY15---
FY14---
FY13---
FY12---
FY11---
Free cash flowOperating cash flow minus capital expenditure
−$400M−$300M−$200M−$100M$0$100MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$336.2M
FY24−$364M
FY23−$384.1M
FY22−$313.2M
FY21−$265.5M
FY20−$251.9M
FY19−$165.8M
FY18−$102.4M
FY17−$79.7M
FY16−$34.2M
FY15−$19.5M
FY14$7M
FY13−$3.7M
FY12−$2.2M
FY11−$6.2M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Iovance Biotherapeutics
  • Healthcare median
−40000%−30000%−20000%−10000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearIovance BiotherapeuticsHealthcare median
FY25−148.4%−30.6%
FY24−226.9%−47%
FY23−37342.3%−58%
FY22-−80.4%
FY21-−71.9%
FY20-−62.2%
FY19-−46.3%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−38.4%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%
FY11-−27.9%